{
  "resourceType" : "ResearchStudy",
  "id" : "2022-500014-26-00",
  "meta" : {
    "lastUpdated" : "2023-04-12T00:00:00.000Z",
    "profile" : ["https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: ResearchStudy</b><a name=\"2022-500014-26-00\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ResearchStudy &quot;2022-500014-26-00&quot; Updated &quot;2023-04-12 00:00:00+0000&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-eclaire-researchstudy.html\">ECLAIREResearchStudy</a></p></div><p><b>ECLAIRESecondarySponsor</b>: <a href=\"Organization/2022-500014-26-00-secondary-sponsor\">Organization/2022-500014-26-00-secondary-sponsor: Reference to secondary sponsor</a></p><p><b>ECLAIRETherapeuticArea</b>: Diseases [C] - Neoplasms [C04]</p><blockquote><p><b>ECLAIRELabel</b></p><blockquote><p><b>url</b></p><code>labelValue</code></blockquote><p><b>value</b>: INDISPONIBLE</p><blockquote><p><b>url</b></p><code>labelType</code></blockquote><p><b>value</b>: Label Type <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (title-type[5.0.0]#human-use &quot;Human use&quot;)</span></p></blockquote><blockquote><p><b>ECLAIRELabel</b></p><blockquote><p><b>url</b></p><code>labelValue</code></blockquote><p><b>value</b>: INDISPONIBLE</p><blockquote><p><b>url</b></p><code>labelType</code></blockquote><p><b>value</b>: Label Type <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (title-type[5.0.0]#acronym &quot;Acronym&quot;)</span></p></blockquote><p><b>ECLAIRERecruitmentPeriod</b>: 2022-06-30 00:00:00+0000 --&gt; (ongoing)</p><p><b>ECLAIREReviewDate</b>: Apr 12, 2023, 12:00:00 AM</p><p><b>identifier</b>: id:\u00a0INDISPONIBLE\u00a0(use:\u00a0OFFICIAL), id:\u00a02022-500014-26-00\u00a0(use:\u00a0SECONDARY)</p><p><b>title</b>: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER</p><p><b>status</b>: active</p><p><b>phase</b>: Research Study Phase <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ResearchStudyPhase[4.0.1]#phase-3 &quot;Phase 3&quot;)</span></p><p><b>category</b>: Regulation Code <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ([not stated] &quot;REG536&quot;)</span>, Reglementation Precision <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ([not stated] &quot;un essai clinique&quot;)</span></p><p><b>condition</b>: Locally-Advanced or Metastatic breast cancer (MBC) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ([not stated])</span>, 10070575 <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span>, 10065430 <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>contact</b>: ph: 0041616881111(WORK),<a href=\"mailto:global.rochegenentechtrials@roche.com\">global.rochegenentechtrials@roche.com</a>, ph: INDISPONIBLE(WORK),<a href=\"mailto:INDISPONIBLE\">INDISPONIBLE</a>, ph: INDISPONIBLE(WORK),<a href=\"mailto:INDISPONIBLE\">INDISPONIBLE</a></p><p><b>location</b>: Countries of recruitment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#BE &quot;Belgium&quot;)</span>, Countries of recruitment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#DE &quot;Germany&quot;)</span>, Countries of recruitment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#ES &quot;Spain&quot;)</span>, Countries of recruitment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#FR &quot;France&quot;)</span>, Countries of recruitment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#HU &quot;Hungary&quot;)</span>, Countries of recruitment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#IT &quot;Italy&quot;)</span>, Countries of recruitment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#PL &quot;Poland&quot;)</span>, Countries of recruitment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#PT &quot;Portugal&quot;)</span></p><p><b>description</b>: INDISPONIBLE</p><p><b>enrollment</b>: <a href=\"Group/2022-500014-26-00-enrollment-group\">Group/2022-500014-26-00-enrollment-group: Reference to group detailing study characteristics</a></p><p><b>sponsor</b>: <a href=\"Organization/2022-500014-26-00-primary-sponsor\">Organization/2022-500014-26-00-primary-sponsor: Reference to primary sponsor</a></p></div>"
  },
  "extension" : [{
    "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-secondary-sponsor",
    "valueReference" : {
      "reference" : "Organization/2022-500014-26-00-secondary-sponsor",
      "type" : "Organization",
      "display" : "Reference to secondary sponsor"
    }
  },
  {
    "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area",
    "valueString" : "Diseases [C] - Neoplasms [C04]"
  },
  {
    "extension" : [{
      "url" : "labelValue",
      "valueString" : "INDISPONIBLE"
    },
    {
      "url" : "labelType",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "http://hl7.org/fhir/title-type",
          "version" : "5.0.0",
          "code" : "human-use",
          "display" : "Human use"
        }],
        "text" : "Label Type"
      }
    }],
    "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-label"
  },
  {
    "extension" : [{
      "url" : "labelValue",
      "valueString" : "INDISPONIBLE"
    },
    {
      "url" : "labelType",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "http://hl7.org/fhir/title-type",
          "version" : "5.0.0",
          "code" : "acronym",
          "display" : "Acronym"
        }],
        "text" : "Label Type"
      }
    }],
    "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-label"
  },
  {
    "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period",
    "valuePeriod" : {
      "start" : "2022-06-30T00:00:00.000Z"
    }
  },
  {
    "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-review-date",
    "valueInstant" : "2023-04-12T00:00:00.000Z"
  }],
  "identifier" : [{
    "use" : "official",
    "value" : "INDISPONIBLE",
    "assigner" : {
      "type" : "Organization",
      "display" : "Reference to primary assigner"
    }
  },
  {
    "use" : "secondary",
    "value" : "2022-500014-26-00",
    "assigner" : {
      "reference" : "Organization/ctis",
      "type" : "Organization",
      "display" : "Reference to secondary assigner"
    }
  }],
  "title" : "A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER",
  "status" : "active",
  "phase" : {
    "coding" : [{
      "system" : "http://terminology.hl7.org/CodeSystem/research-study-phase",
      "version" : "4.0.1",
      "code" : "phase-3",
      "display" : "Phase 3"
    }],
    "text" : "Research Study Phase"
  },
  "category" : [{
    "coding" : [{
      "display" : "REG536"
    }],
    "text" : "Regulation Code"
  },
  {
    "coding" : [{
      "display" : "un essai clinique"
    }],
    "text" : "Reglementation Precision"
  }],
  "condition" : [{
    "id" : "ResearchStudy.condition:diseaseCondition",
    "coding" : [{
      "display" : "Locally-Advanced or Metastatic breast cancer (MBC)"
    }],
    "text" : "Locally-Advanced or Metastatic breast cancer (MBC)"
  },
  {
    "id" : "ResearchStudy.condition:medDRACondition",
    "text" : "10070575"
  },
  {
    "id" : "ResearchStudy.condition:medDRACondition",
    "text" : "10065430"
  }],
  "contact" : [{
    "extension" : [{
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name",
      "valueHumanName" : {
        "use" : "official",
        "family" : "Trial Information Support Line-TISL, Switzerland",
        "given" : ["Head of EU"]
      }
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address",
      "valueAddress" : {
        "use" : "work",
        "type" : "physical",
        "line" : ["INDISPONIBLE"],
        "city" : "INDISPONIBLE",
        "postalCode" : "INDISPONIBLE",
        "country" : "INDISPONIBLE"
      }
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-affiliation",
      "valueString" : "INDISPONIBLE"
    }],
    "telecom" : [{
      "system" : "phone",
      "value" : "0041616881111",
      "use" : "work"
    },
    {
      "system" : "email",
      "value" : "global.rochegenentechtrials@roche.com",
      "use" : "work"
    }]
  },
  {
    "extension" : [{
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name",
      "valueHumanName" : {
        "use" : "official",
        "family" : "INDISPONIBLE",
        "given" : ["INDISPONIBLE"]
      }
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address",
      "valueAddress" : {
        "use" : "work",
        "type" : "physical",
        "line" : ["INDISPONIBLE"],
        "city" : "INDISPONIBLE",
        "postalCode" : "INDISPONIBLE",
        "country" : "INDISPONIBLE"
      }
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-affiliation",
      "valueString" : "INDISPONIBLE"
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system",
          "version" : "0.1.0",
          "code" : "SCI",
          "display" : "Scientifique / Scientific"
        }],
        "text" : "Contact Type"
      }
    }],
    "telecom" : [{
      "system" : "phone",
      "value" : "INDISPONIBLE",
      "use" : "work"
    },
    {
      "system" : "email",
      "value" : "INDISPONIBLE",
      "use" : "work"
    }]
  },
  {
    "extension" : [{
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name",
      "valueHumanName" : {
        "use" : "official",
        "family" : "INDISPONIBLE",
        "given" : ["INDISPONIBLE"]
      }
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address",
      "valueAddress" : {
        "use" : "work",
        "type" : "physical",
        "line" : ["INDISPONIBLE"],
        "city" : "INDISPONIBLE",
        "postalCode" : "INDISPONIBLE",
        "country" : "INDISPONIBLE"
      }
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-affiliation",
      "valueString" : "INDISPONIBLE"
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system",
          "version" : "0.1.0",
          "code" : "PUB",
          "display" : "Publique / Public"
        }],
        "text" : "Contact Type"
      }
    }],
    "telecom" : [{
      "system" : "phone",
      "value" : "INDISPONIBLE",
      "use" : "work"
    },
    {
      "system" : "email",
      "value" : "INDISPONIBLE",
      "use" : "work"
    }]
  }],
  "location" : [{
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "BE",
      "display" : "Belgium"
    }],
    "text" : "Countries of recruitment"
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "DE",
      "display" : "Germany"
    }],
    "text" : "Countries of recruitment"
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "ES",
      "display" : "Spain"
    }],
    "text" : "Countries of recruitment"
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "FR",
      "display" : "France"
    }],
    "text" : "Countries of recruitment"
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "HU",
      "display" : "Hungary"
    }],
    "text" : "Countries of recruitment"
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "IT",
      "display" : "Italy"
    }],
    "text" : "Countries of recruitment"
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "PL",
      "display" : "Poland"
    }],
    "text" : "Countries of recruitment"
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "PT",
      "display" : "Portugal"
    }],
    "text" : "Countries of recruitment"
  }],
  "description" : "INDISPONIBLE",
  "enrollment" : [{
    "reference" : "Group/2022-500014-26-00-enrollment-group",
    "type" : "Group",
    "display" : "Reference to group detailing study characteristics"
  }],
  "sponsor" : {
    "reference" : "Organization/2022-500014-26-00-primary-sponsor",
    "type" : "Organization",
    "display" : "Reference to primary sponsor"
  }
}